Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CD40L in autoimmunity and mucosally induced tolerance
Mi-Na Kweon, Hiroshi Kiyono
Mi-Na Kweon, Hiroshi Kiyono
Published January 15, 2002
Citation Information: J Clin Invest. 2002;109(2):171-173. https://doi.org/10.1172/JCI14930.
View: Text | PDF
Commentary

CD40L in autoimmunity and mucosally induced tolerance

  • Text
  • PDF
Abstract

Authors

Mi-Na Kweon, Hiroshi Kiyono

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Models for the effects on mucosally induced tolerance of perturbing the ...
Models for the effects on mucosally induced tolerance of perturbing the CD40L-CD40 interaction. (a) In the untreated wild-type mouse, CD40 on dendritic cells (DCs) and other APCs interacts with CD40L expressed on T cells of several subsets, including CD4 and CD8 cells, as well as a CD25 CD4 population of regulatory T cells (Tr). This interaction can lead to both active, antigen-specific CTL responses and the suppression of Th function and inflammation. The latter effects appear to be implicated in mucosally induced tolerance to dietary antigens and endogenous bacteria. (b) As shown by Hänninen et al. in this issue of the JCI (8), transient treatment with mAb anti-CD40L can prevent induction of CTLs, while apparently leaving some of the other responses intact. Thus, mucosally induced tolerance is not compromised by this treatment. (c) In case of the permanent blockage of CD40L-CD40, as occurs in CD40L–/– mice, the additional loss of some immunosuppressive signaling cascade and/or of a population of Tr cells prevents mucosally induced tolerance.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts